A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae

Description

The purpose of this study is to understand why some people experience long term effects, such as shortness of breath and fatigue, after a severe COVID-19 infection

Conditions

COVID-19

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to understand why some people experience long term effects, such as shortness of breath and fatigue, after a severe COVID-19 infection

Uncover Mechanisms Underlying the Development of Chronic Lung Sequelae Post COVID-19

A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae

Condition
COVID-19
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic Minnesota, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥18 years at screening, PCR confirmed COVID19 illness (+PCR defines day 0 of illness), hospitalization for COVID-19, absence of pre-existing history of interstitial lung disease, or significant other lung disease.
  • * Severity of illness will be categorized as moderate disease (supplemental oxygen need 1-8L at any time during hospitalization), severe disease (need for high flow oxygen delivery ≥8L at any time during hospitalization) and critical illness (need for ICU admission or mechanical ventilation).
  • * Age ≥18 years at screening
  • * PCR confirmed COVID-19 cases who had nonsymptomatic or mild acute infection that do not require hospitalization 7,48,49
  • * Absence of pre-existing history of interstitial lung disease, or significant other lung disease, absence of any ongoing respiratory and systemic symptoms.
  • * Inability to provide informed consent, evidence of pre-existing interstitial lung disease or chronic lung disease;
  • * Active cigarette smoking, vaping or other inhalation use.
  • * Immunocompromised host status due to ongoing therapy with methotrexate, CellCept, azathioprine, rituximab, cyclophosphamide or other biologic agents;
  • * \> 20 pack year smoking history.
  • * History of chemotherapy or radiation therapy in the last two years; and pregnancy.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Robert Vassallo, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2027-08